Our Partners
Thank you to all our partner organisations:
Boehringer Ingelheim has 100 years of heritage in respiratory disease.
Since 1921 we have emerged as a leader in this disease area, having developed and launched treatments for a range of respiratory conditions including lung cancer, asthma, chronic obstructive pulmonary disease (COPD), treatment of adults with idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Our continued focus is on improving the life of patients suffering from debilitating respiratory diseases.
PC-GB-105963 Date of preparation; November 2021
https://go.boehringer.com/pme
This website contains promotional information about Boehringer Ingelheim marketed medicines.
Boehringer Ingelheim (BI) has provided financial support to ARNS as a partnership resulting in various communication opportunities throughout 2025.
Astrazeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas- Oncology, Cardiovascular, Renal & Metabolism and Respiratory. For more information, please visit www.astrazeneca.co.uk
Based in Parma, Italy,
Chiesi Farmaceutici is an international research-focused biopharmaceuticals group with over 85 years’ experience in the pharmaceutical sector operating in 30 countries, employing around 6,000 people. Chiesi develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. Chiesi Limited is headquartered in Manchester employing over 400 people. For more information, please visit www.chiesi.uk.com
GSK are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively
impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
NP-GB-RS-COCO-230002 | January 2024
Trudell Medical UK works with patients, caregivers, and healthcare professionals to improve respiratory health, helping patients breathe better and live fuller lives. As a leader in respiratory care, we manufacture and market some of the most trusted brands in the industry, including the AeroChamber brand of spacers, Aerobika OPEP devices, and AEROECLIPSE* BAN* nebulisers, all designed to enhance patient outcomes and quality of life.